Nothing Special   »   [go: up one dir, main page]

IT1393338B1 - Uso terapeutico della metadoxina come inibitore della fibrosi epatica. - Google Patents

Uso terapeutico della metadoxina come inibitore della fibrosi epatica.

Info

Publication number
IT1393338B1
IT1393338B1 ITMI2009A000333A ITMI20090333A IT1393338B1 IT 1393338 B1 IT1393338 B1 IT 1393338B1 IT MI2009A000333 A ITMI2009A000333 A IT MI2009A000333A IT MI20090333 A ITMI20090333 A IT MI20090333A IT 1393338 B1 IT1393338 B1 IT 1393338B1
Authority
IT
Italy
Prior art keywords
metadoxine
inhibitor
therapeutic use
liver fibrosis
fibrosis
Prior art date
Application number
ITMI2009A000333A
Other languages
English (en)
Inventor
Massimo Baldacci
Original Assignee
Baldacci Lab Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baldacci Lab Spa filed Critical Baldacci Lab Spa
Priority to ITMI2009A000333A priority Critical patent/IT1393338B1/it
Priority to PT107125197T priority patent/PT2403495E/pt
Priority to EP10712519.7A priority patent/EP2403495B1/en
Priority to US13/138,536 priority patent/US20120029031A1/en
Priority to ES10712519.7T priority patent/ES2544780T3/es
Priority to PCT/IB2010/050930 priority patent/WO2010100619A1/en
Publication of ITMI20090333A1 publication Critical patent/ITMI20090333A1/it
Application granted granted Critical
Publication of IT1393338B1 publication Critical patent/IT1393338B1/it

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415Pyridoxine, i.e. Vitamin B6
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4425Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ITMI2009A000333A 2009-03-06 2009-03-06 Uso terapeutico della metadoxina come inibitore della fibrosi epatica. IT1393338B1 (it)

Priority Applications (6)

Application Number Priority Date Filing Date Title
ITMI2009A000333A IT1393338B1 (it) 2009-03-06 2009-03-06 Uso terapeutico della metadoxina come inibitore della fibrosi epatica.
PT107125197T PT2403495E (pt) 2009-03-06 2010-03-04 Metadoxina para utilização como inibidor da fibrose hepática
EP10712519.7A EP2403495B1 (en) 2009-03-06 2010-03-04 Metadoxine for use as inhibitor of hepatic fibrosis.
US13/138,536 US20120029031A1 (en) 2009-03-06 2010-03-04 Metadoxine for use as inhibitor of hepatic fibrosis
ES10712519.7T ES2544780T3 (es) 2009-03-06 2010-03-04 Metadoxina para su uso como inhibidor de fibrosis hepática
PCT/IB2010/050930 WO2010100619A1 (en) 2009-03-06 2010-03-04 Metadoxine for use as inhibitor of hepatic fibrosis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITMI2009A000333A IT1393338B1 (it) 2009-03-06 2009-03-06 Uso terapeutico della metadoxina come inibitore della fibrosi epatica.

Publications (2)

Publication Number Publication Date
ITMI20090333A1 ITMI20090333A1 (it) 2010-09-07
IT1393338B1 true IT1393338B1 (it) 2012-04-20

Family

ID=41202480

Family Applications (1)

Application Number Title Priority Date Filing Date
ITMI2009A000333A IT1393338B1 (it) 2009-03-06 2009-03-06 Uso terapeutico della metadoxina come inibitore della fibrosi epatica.

Country Status (6)

Country Link
US (1) US20120029031A1 (it)
EP (1) EP2403495B1 (it)
ES (1) ES2544780T3 (it)
IT (1) IT1393338B1 (it)
PT (1) PT2403495E (it)
WO (1) WO2010100619A1 (it)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011061743A1 (en) * 2009-11-18 2011-05-26 Alcobra Ltd. Metadoxine and derivatives thereof for use in the treatment of inflammation and immune-related disorders
BR112015006642B1 (pt) * 2012-09-26 2022-08-02 Eurodrug Laboratories B.V Composição farmacêutica de liberação prolongada compreendendo metadoxina e prednisona
EP3035221A1 (en) * 2014-12-19 2016-06-22 John Rovnan Systems and methods for managing an electronic database

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1131856B (it) * 1980-06-30 1986-06-25 Baldacci Lab Spa Composizione farmaceutica per il trattamento di intossicazioni alcooliche
KR100877600B1 (ko) * 2006-11-30 2009-01-08 재단법인서울대학교산학협력재단 메타독신 및 마늘유를 유효성분으로 함유하는 알코올성지방간 및 지방간성 간염의 예방 및 치료용 약학 조성물

Also Published As

Publication number Publication date
EP2403495A1 (en) 2012-01-11
PT2403495E (pt) 2015-09-17
ES2544780T3 (es) 2015-09-03
ITMI20090333A1 (it) 2010-09-07
EP2403495B1 (en) 2015-05-20
WO2010100619A1 (en) 2010-09-10
US20120029031A1 (en) 2012-02-02

Similar Documents

Publication Publication Date Title
SMT201600135B (it) Nuovi inibitori della s-nitrosoglutatione riduttasi
SMT201500206B (it) Composti spiro-ossindolici e loro uso come agenti terapeutici
BRPI1009315A2 (pt) agentes anti-inflamatórios
BRPI1014956A2 (pt) agentes antinflamatórios.
SMT201400008B (it) Uso di betanecolo per il trattamento di xerostomia
DK2246336T3 (da) Fibroseinhibitor
BRPI0913945A2 (pt) agentes anti-inflamatórios
BRPI1005670A8 (pt) composições adjuvantes e processos de uso.
BR112012004335A2 (pt) composto, composição farmacêutica, e, uso do composto.
SMT201400057B (it) Composizione per il trattamento della fibrosi cistica
BRPI1014316A2 (pt) composição, e, uso de uma composição
BRPI1007494A2 (pt) composto e uso do mesmo
SMT201500264B (it) Mutanti della frataxina
BRPI1015091A2 (pt) novo uso
BRPI1011036A2 (pt) uso
FI20095644A (fi) Ulokkeen muodostaminen
BRPI0915905A2 (pt) uso de derivados de pirimidilaminobenzamida para o tratamento de fibrose
BRPI0909840A2 (pt) Uso de 4-tio-2-deoxinucleosídios
FI20100404A0 (fi) Yhteysalus
BR112012002311A2 (pt) composto, composição farmacêutica, e, uso do composto.
BRPI0908756A2 (pt) Uso combinado de derivado do colestanol
BRPI0822637A2 (pt) Uso de lanosta-8, 24-dien-3-óis
IT1393338B1 (it) Uso terapeutico della metadoxina come inibitore della fibrosi epatica.
SMT201600301B (it) USO TERAPEUTICO DELLA PROTEINAß2- MICROGLOBULINA
DK2265778T3 (da) Muranker